Mark J. Rosenblum - Feb 20, 2024 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Exec VP Finance, CFO
Signature
/s/ Mark J. Rosenblum
Stock symbol
SLRX
Transactions as of
Feb 20, 2024
Transactions value $
$0
Form type
4
Date filed
2/22/2024, 04:37 PM
Previous filing
Feb 15, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLRX Stock Option (right to buy) Award $0 +22.5K $0.00 22.5K Feb 20, 2024 Common Stock 22.5K $0.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options are vested on February 20, 2025, and 1/36 of the remaining options vest on each monthly anniversary thereafter for 36 months.